Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Up 212.4% in January

Abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 77,800 shares, an increase of 212.4% from the December 31st total of 24,900 shares. Based on an average daily trading volume, of 93,900 shares, the days-to-cover ratio is currently 0.8 days.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Hedge funds and other institutional investors have recently modified their holdings of the stock. Future Financial Wealth Managment LLC purchased a new position in shares of Abrdn Life Sciences Investors during the third quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new position in Abrdn Life Sciences Investors during the third quarter valued at approximately $148,000. Sanctuary Advisors LLC purchased a new position in Abrdn Life Sciences Investors in the second quarter valued at $154,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Abrdn Life Sciences Investors during the 4th quarter valued at approximately $160,000. Finally, Kapstone Financial Advisors LLC purchased a new stake in Abrdn Life Sciences Investors during the 3rd quarter worth approximately $177,000. Institutional investors own 32.21% of the company’s stock.

Abrdn Life Sciences Investors Price Performance

Abrdn Life Sciences Investors stock opened at $14.13 on Wednesday. The stock’s 50 day simple moving average is $13.76 and its two-hundred day simple moving average is $14.62. Abrdn Life Sciences Investors has a fifty-two week low of $12.76 and a fifty-two week high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 10th. Investors of record on Thursday, November 21st were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 14.15%. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 21st.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.